Terms: = Breast cancer AND XPO1, DKFZp686B1823, 7514, ENSG00000082898, O14980, CRM1 AND Prognosis
4 results:
1. KPT-330 and Y219 exert a synergistic antitumor effect in triple-negative breast cancer through inhibiting NF-κB signaling.
Wen T; Geng M; Bai E; Wang X; Miao H; Chen Z; Zhou H; Wang J; Shi J; Zhang Y; Lei M; Zhu Y
FEBS Open Bio; 2023 Apr; 13(4):751-762. PubMed ID: 36847599
[TBL] [Abstract] [Full Text] [Related]
2. Selinexor demonstrates anti-tumor efficacy in paired patient-derived xenograft models and hydrogel-embedded histoculture drug sensitivity test of penile cancer.
He Y; Mei J; Hao H; Liu F; Yi Y; Hu C; Zou F; Lu X
J Cancer Res Clin Oncol; 2023 Aug; 149(10):6931-6941. PubMed ID: 36840755
[TBL] [Abstract] [Full Text] [Related]
3. Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody.
Martini S; Figini M; Croce A; Frigerio B; Pennati M; Gianni AM; De Marco C; Daidone MG; Argueta C; Landesman Y; Zaffaroni N; Satta A
Cells; 2020 Oct; 9(10):. PubMed ID: 33023194
[TBL] [Abstract] [Full Text] [Related]
4. Ultraconserved long non-coding RNA uc.63 in breast cancer.
Marini A; Lena AM; Panatta E; Ivan C; Han L; Liang H; Annicchiarico-Petruzzelli M; Di Daniele N; Calin GA; Candi E; Melino G
Oncotarget; 2017 May; 8(22):35669-35680. PubMed ID: 27447964
[TBL] [Abstract] [Full Text] [Related]
